{
  "ticker": "INCY",
  "company_name": "Incyte Corporation",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03334396",
      "title": "A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Atopic Dermatitis",
      "start_date": "2017-11-23",
      "completion_date": "2019-08-16",
      "enrollment": 0,
      "sponsor": "Eli Lilly and Company"
    },
    {
      "nct_id": "NCT02872714",
      "title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "UC (Urothelial Cancer)",
      "start_date": "2017-01-12",
      "completion_date": "2022-02-01",
      "enrollment": 0,
      "sponsor": "Incyte Corporation"
    },
    {
      "nct_id": "NCT03257644",
      "title": "A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Atopic Dermatitis",
      "start_date": "2017-09-21",
      "completion_date": "2020-10-07",
      "enrollment": 0,
      "sponsor": "Incyte Corporation"
    },
    {
      "nct_id": "NCT03428100",
      "title": "A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Atopic Dermatitis",
      "start_date": "2018-05-15",
      "completion_date": "2023-04-20",
      "enrollment": 0,
      "sponsor": "Eli Lilly and Company"
    },
    {
      "nct_id": "NCT05359692",
      "title": "INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma",
      "start_date": "2023-03-01",
      "completion_date": "2025-01-11",
      "enrollment": 0,
      "sponsor": "Incyte Biosciences International S\u00e0rl"
    },
    {
      "nct_id": "NCT02355431",
      "title": "Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)",
      "start_date": "2014-12",
      "completion_date": "2015-09",
      "enrollment": 0,
      "sponsor": "Incyte Corporation"
    },
    {
      "nct_id": "NCT02711137",
      "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumors",
      "start_date": "2016-05-18",
      "completion_date": "2019-02-13",
      "enrollment": 0,
      "sponsor": "Incyte Corporation"
    },
    {
      "nct_id": "NCT06663722",
      "title": "Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Chronic Graft Versus Host Disease, cGVHD",
      "start_date": "2025-05-05",
      "completion_date": "2030-05-05",
      "enrollment": 0,
      "sponsor": "University of Miami"
    },
    {
      "nct_id": "NCT04809467",
      "title": "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma",
      "start_date": "2021-09-16",
      "completion_date": "2024-10-22",
      "enrollment": 0,
      "sponsor": "Incyte Corporation"
    },
    {
      "nct_id": "NCT03670069",
      "title": "Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma",
      "start_date": "2019-09-30",
      "completion_date": "2024-05-06",
      "enrollment": 0,
      "sponsor": "Fred Hutchinson Cancer Center"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 13,
      "PHASE2": 15,
      "PHASE1": 9,
      "PHASE1, PHASE2": 8,
      "": 4,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 22,
      "WITHDRAWN": 3,
      "TERMINATED": 8,
      "RECRUITING": 10,
      "ACTIVE_NOT_RECRUITING": 2,
      "NO_LONGER_AVAILABLE": 1,
      "AVAILABLE": 1,
      "UNKNOWN": 1,
      "NOT_YET_RECRUITING": 1,
      "APPROVED_FOR_MARKETING": 1
    },
    "active_trials": 12,
    "completed_trials": 22,
    "conditions": [
      "Acute Myeloid Leukemia",
      "Aplastic Anemia",
      "Atopic Dermatitis",
      "Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm",
      "Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent",
      "Breast Cancer",
      "COVID-19",
      "Chronic Graft Versus Host Disease, cGVHD",
      "Chronic Graft-versus-host Disease",
      "Chronic Graft-versus-host Disease (cGVHD)",
      "Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma",
      "Diabetic Kidney Disease",
      "Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)",
      "Glioblastoma Multiforme",
      "Graft-versus-host Disease (GVHD)",
      "Healthy Participants",
      "Hidradenitis Suppurativa (HS)",
      "Hodgkin Lymphoma",
      "Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia",
      "MDS/MPN",
      "MPN (Myeloproliferative Neoplasms)",
      "Mantle Cell Lymphoma, MCL",
      "Melanoma",
      "Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies, Recurrent Head and Neck Squamous Cell Carcinoma",
      "Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma",
      "Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Skin Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Skin Melanoma, Stage IIIC Uveal Melanoma, Stage IV Skin Melanoma, Stage IV Uveal Melanoma",
      "Myelodysplastic Syndromes",
      "Myelofibrosis",
      "Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis",
      "Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma",
      "Non-segmental Vitiligo",
      "Prurigo Nodularis",
      "Psoriasis",
      "STAT1 Gain-of-Function Disease",
      "Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult",
      "Solid Tumor",
      "Solid Tumors",
      "Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)",
      "Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors",
      "UC (Urothelial Cancer)",
      "Unresectable or Metastatic Solid Tumors",
      "Urothelial Carcinoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:02:47.370590",
    "search_query": "Incyte Corporation",
    "url": "https://clinicaltrials.gov/search?term=Incyte+Corporation"
  }
}